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AbstrACt 
Purpose Low-income and middle-income countries 
such as Tanzania experience a high prevalence of non-
communicable diseases (NCDs), including anaemia. 
Studying if and how anaemia affects growth, placenta 
development, epigenetic patterns and newborns’ risk of 
NCDs may provide approaches to prevent NCDs.
Participants The FOETALforNCD (FOetal Exposure and 
Epidemiological Transitions: the role of Anaemia in early 
Life for Non-Communicable Diseases in later life) Study 
is a population-based preconception, pregnancy and 
birth cohort study (n=1415, n=538, n=427, respectively), 
conducted in a rural region of North-East Tanzania. 
All participants were recruited prior to conception or 
early in pregnancy and followed throughout pregnancy 
as well as at birth. Data collection included: maternal 
blood, screening for NCDs and malaria, ultrasound in 
each trimester, neonatal anthropometry at birth and at 
1 month of age, cord blood, placental and cord biopsies for 
stereology and epigenetic analyses.
Findings to date At preconception, the average age, 
body mass index and blood pressure of the women were 
28 years, 23 kg/m2 and 117/75 mm Hg, respectively. In 
total, 458 (36.7%) women had anaemia (haemoglobin 
Hb <12 g/dL) and 34 (3.6%) women were HIV-positive at 
preconception. During pregnancy 359 (66.7%) women had 
anaemia of which 85 (15.8%) women had moderate-to-
severe anaemia (Hb ≤9 g/dL) and 33 (6.1%) women had 
severe anaemia (Hb ≤8 g/dL). In total, 185 (34.4%) women 
were diagnosed with malaria during pregnancy.
Future plans The project will provide new knowledge 
on how health, even before conception, might modify 
the risk of developing NCDs and how to promote better 
health during pregnancy. The present project ended 
data collection 1 month after giving birth, but follow-up 
is continuing through regular monitoring of growth and 
development and health events according to the National 
Road Map Strategic Plan in Tanzania. This data will 
link fetal adverse event to childhood development, and 
depending on further grant allocation, through a life course 
follow-up.
IntroduCtIon
Non-communicable diseases (NCDs) are 
a major public health concern1 2 causing 
30 million deaths per year, of which 70% 
occur in low-income and middle-income 
countries (LMICs).3 NCDs are anticipated 
to overtake infectious diseases as the primary 
strengths and limitations of this study
 ► The uniqueness of this study lies in the establish-
ment of a population followed continuously before 
and during pregnancy with accurate estimation of 
gestational age using early ultrasound and detailed, 
high-quality data including fetal weight and placen-
tal blood flow monitoring.
 ► To the best of our knowledge this is the largest 
preconception study (n=1415) conducted in a rural 
African setting.
 ► The study involved stringent screening of important 
factors influencing fetal growth such as anaemia, 
prepregnancy nutritional status, gestational hyper-
tensive disorders, diabetes, malaria and HIV.
 ► The study included a substantial biobank of plasma, 
serum, cord blood and placenta, including stereolo-
gy and epigenetic markers.
 ► The study succeeded in recruiting more pregnant 
women than expected, but with a lower prevalence 
of anaemia than anticipated, therefore some out-
comes may have less power including birth out-
comes in severe anaemia. Yet, the higher number 
of mild anaemia cases might relate more to areas of 
the world where mild pregnancy anaemia prevails.
 o
n
 30 June 2019 by guest. Protected by copyright.
http://bmjopen.bmj.com/
BM
J O
pen: first published as 10.1136/bmjopen-2018-024861 on 22 May 2019. Downloaded from 
2 Hjort L, et al. BMJ Open 2019;9:e024861. doi:10.1136/bmjopen-2018-024861
Open access 
cause of death in Africa by 2030.3 Here, cardiometabolic 
diseases develop earlier and increase faster than in the 
‘western’ world.3 
Anaemia is a global health problem affecting 24% of preg-
nant women in Denmark to 36%–60% of pregnant women 
in LMICs such as Tanzania.4 Anaemia in pregnancy may 
decrease birth weight,5 and low birth weight (LBW) is asso-
ciated with an increased risk of NCDs.6 Hales and Barker’s 
fetal programming hypothesis, linking LBW with risk for 
developing cardiometabolic diseases in later life,7 prompted 
us to hypothesise that anaemia before conception or during 
pregnancy could play an essential role in NCD program-
ming. The alarmingly high prevalence of anaemia in LMICs 
is a key health threat, but is also an opportunity to reveal 
the role of anaemia in the global epidemic of NCDs and 
provide potential approaches to prevent NCDs, in partic-
ular, in societies in fast transition.
During pregnancy, anaemia is defined as haemoglobin 
(Hb) <11 g/dL, (preconception: Hb <12 g/dL).4 A major 
cause of anaemia is iron deficiency which compromises 
the fetal iron supply,8 9 and severe–moderate anaemia 
(Hb ≤8 or 9 g/dL) is associated with increased risk of 
being born small for gestational age (GA).5 10 Anaemia 
in the first two trimesters has been associated with 
decreased fetal growth and preterm delivery whereas the 
consequences of anaemia in the third trimester are less 
clear.5 11 12 Iron supplementation has indeed been shown 
to improve birth weight outcomes.5 13–15 The insulin-like 
growth factor (IGF) axis has been suggested to play a role 
in fetal response to anaemia.16 It is also debated whether 
high Hb concentration in pregnancy has a positive or 
negative effect on birth and childhood outcomes, that is, 
it has been shown that high Hb concentrations (≥14.6 g/
dL) were associated with an increased risk of stillbirths in a 
Swedish case-control study,17 and furthermore that reduc-
tion in Hb concentration from early pregnancy to delivery 
was associated with increased birth weight.18 Anaemia in 
pregnancy has also been associated with adverse develop-
ment of the placenta15 19 including increase in size and 
vascularity.20 In the placental villous bed, a switch from 
branching to non-branching angiogenesis in weeks 20–25 
of pregnancy ensures proper placental development 
to accommodate the increasing nutrient and oxygen 
demand of the growing fetus.21 Anaemia may affect 
the oxygen tension and hence the vascular endothelial 
growth factor A (VEGF-A) and placental growth factor 
(PlGF) balance and the villous branching pattern.21 22
Tanzania is undergoing fast epidemiological transition 
from a population affected by anaemia and infectious 
diseases, towards NCDs within one generation.23 24 Malaria 
is prevalent in both Tanzania and many other LMICs, and 
is a major risk factor for anaemia and LBW.25 Therefore, 
malaria should also be considered when studying the effect 
of anaemia on pregnancy outcome. In spite of a high preva-
lence of anaemia and its potential severe consequences for 
mother and offspring, there are only few studies in LMICs 
that have followed women before pregnancy, throughout 
pregnancy until delivery,8 26 27 and none, to the best our 
knowledge, linking anthropometry, fetal growth, infections, 
growth hormones, micronutrients, placental blood flow, 
epigenetics, placental stereology and histology.
The FOETALforNCD (FOetal Exposure and Epide-
miological Transitions: the role of Anaemia in early Life 
for Non-Communicable Diseases in later life) Study is a 
population-based preconception (n=1415), pregnancy 
(n=538) and birth (n=427) study, conducted in a rural 
region of North-East Tanzania. By using an interdisciplinary 
approach, the overall objective of this study is to evaluate 
anaemia-induced alterations of fetal and placental develop-
ment and susceptibility to NCDs, taking into consideration 
the contribution of malaria. We anticipate the project will 
provide new knowledge on how health, even before concep-
tion, might modify the risk of developing NCDs and how 
to promote better health during pregnancy. The specific 
objectives are described below.
the preconception study
The objective is to characterise the health of women 
from a rural region in Tanzania, before conception. We 
will examine the prevalence and risk factors of anaemia 
(including malaria, micronutrient deficiencies and socio-
economic determinants) as well as of hypertension, 
diabetes and fertility.
the pregnancy study
The objective is to evaluate the effect of anaemia on 
fetal and placental development. We will evaluate how 
first-trimester and second-trimester compared with 
third-trimester anaemia and/or malaria alters fetal and 
placental development and later neonatal body composi-
tion. Placental development will be evaluated as degree of 
villous branching. Finally, we will characterise how first-tri-
mester, second-trimester and third-trimester anaemia 
and/or malaria may change the VEGF-A/PlGF balance 
and the IGF-axis.
the -omics study
The objective of the -omics studies are to explore genetic 
variation (maternal and fetal), genome-wide DNA meth-
ylation and consequent RNA expression in cord blood 
and placenta from pregnancies affected by anaemia and/
or malaria compared with controls. Epigenetic variation 
established in utero has indeed emerged as a candidate 
mediator of long-term programming of NCDs.28 29 Char-
acterisation of epigenetic changes after exposure to 
anaemia may potentially enable us to detect biomarkers 
to identify groups at risk of developing NCDs.
In this paper we present the overall set-up of the inter-
disciplinary study, including selection and baseline char-
acterisation of the participating population.
Cohort desCrIPtIon
study setting
The field studies were conducted in Korogwe, Tanga 
Region, North-Eastern Tanzania (figure 1). The central 
field site was the Maternity Ward and the Reproductive 
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and Child Health Clinic at Magunga Korogwe District 
Hospital (KDH). Mobile clinics were set up in 48 villages 
in the two districts, and 17 dispensaries (including Kwan-
dolwa, Kerenge, Segera, Mgombezi, Makuyuni and 
Mbaghai) functioned as outreach satellite sites supporting 
the antenatal care provided by the study team (figure 1). 
Clinical investigations and sample collection took place 
at KDH, the dispensaries and mobile clinics in the catch-
ment areas, whereas all follow-up activities during preg-
nancy were performed at KDH.
study groups and recruitment
Non-pregnant women were invited to participate in the 
preconception study. Sensitisation campaigns were held 
to ensure a sufficient number of participants. A total of 
2629 women was screened for inclusion between July 2014 
and December 2015. The inclusion criteria were based on 
a high likelihood of becoming pregnant within the study 
period and included: age between 18–40 years, a nega-
tive urine pregnancy test, not having tried to conceive 
for more than two consecutive years (regarded as subfer-
tile), no usage of modern contraceptive methods except 
condoms, not having a child less than 9 months old, living 
in an accessible area, and on conception willing to attend 
antenatal care and give birth at KDH. The women were 
invited to participate in the pregnancy study if concep-
tion occurred between July 2014 and March 2016. To 
ensure early pregnancy inclusion, women were invited to 
report for pregnancy testing every third month or if they 
suspected they were pregnant.
The pregnancy study population was supplemented 
with screening of 445 women in early pregnancy from 
April 2015 to March 2016. These pregnant women 
were recruited on a 1:1 basis with a Hb ≤8 g/dL (severe 
anaemia) or Hb 8.1–10.9 g/dL (mild–moderate anaemia): 
Hb ≥11 g/dL (non-anaemic), and with a GA of ≤14 weeks 
based on ultrasound. Follow-up of pregnant women was 
completed in December 2016 when the last woman in the 
cohort gave birth.
Patient and public involvement
Patients or the public were not involved in the design of 
the study concept and protocol, but the research ques-
tions and outcome measures were developed considering 
the women included and disease patterns observed in 
our previous Strategies TO Prevent Pregnancy-Associ-
ated Malaria (STOPPAM) Study conducted in the same 
region.30 However, the logistic implementation of the 
present study including recruitment and retaining partic-
ipants was conducted in close collaboration with the local 
communities and personnel in the governmental health 
systems.
sample size calculations
Sample size calculation was originally based on the 
observed effect of severe anaemia (Hb ≤8 g/dL) in the 
Figure 1 Map of Korogwe district and the dispensaries in the study.
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second trimester on z-score of birth weight (−0.31) in 
the STOPPAM Study30 conducted in the same area, with 
a significance level of 0.05, power of 0.80 and assuming 
15% lost to follow-up. With balanced inclusion into the 
study, we aimed to enrol 480 pregnant women in the first 
trimester on a 1:2 basis as the severe anaemia group (Hb 
≤8 g/dL) versus a group that did not have severe anaemia. 
The latter group was further divided into two groups 
(8.1–10.9 g/dL and ≥11 g/dL). However, the percentage 
of women with severe anaemia was much lower than antic-
ipated. Many of our aims are exploratory, not all depend 
on birth weight alteration, and the effect on placental 
development, vascularisation, the IGF-axis and epigenetic 
alterations might already be observed when moderate–
mild anaemia is present, although the exact effect size is 
not known. It was therefore decided to continue with the 
study but by including the participants in a 1:1 ratio (Hb 
<11 g/dL vs Hb ≥11 g/dL). This might have resulted in 
too little power to detect the actual difference in birth 
weight, but still helps achieve the other objectives.
In addition, we aimed to include 1500 non-pregnant 
women irrespective of Hb levels, since it is unknown 
whether the effect of anaemia on developmental 
outcomes, including epigenetics, is continuous. Assuming 
that 30% would become pregnant within the project time 
line, and that 60% would be identified, we expected to 
include at least 270 pregnant women.
dAtA ColleCtIon
An overview of the study activities and methods is shown 
in figure 2 and table 1.
socioeconomic status, medical history and clinical 
examination
The following characteristics were documented at inclu-
sion: ethnicity, socioeconomic status (based on housing, 
education and occupation), religion, partner character-
istics (age, ethnicity, education and occupation), contra-
ceptive methods, gravidity history, medical history and 
obstetric history, substance abuse, anthropometry, blood 
pressure (BP), Hb, diabetes, malaria and HIV. Intestinal 
helminths were tested in a subgroup of 486 women. 
Women with an average systolic BP ≥140 mm Hg and/or 
diastolic BP ≥90 mm Hg were scheduled for a follow-up 
visit to confirm BP status. Diabetes was screened for by 
measurement of blood glucose and HbA1c. If glucose 
levels were ≥11.1 mmol/L the woman was scheduled for a 
fasting blood glucose test.
Figure 2 Overview of study activities. 
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During pregnancy, at all antenatal visits, the women 
were monitored for anthropometry, anaemia, infections 
and hypertensive disorders. Sickle cell trait, thalassaemia 
and glucose-6-phosphate dehydrogenase deficiency were 
examined, and an oral glucose tolerance test was done 
during pregnancy at 32–34 weeks.
All women were offered daily iron and folic acid supple-
mentation from the time pregnancy was recognised and 
until delivery (combination tablet of 200 mg ferrous 
sulfate [~43 mg elemental iron] and 400 µg folate per day 
[Ferrolic–LF, Laboratory and Allied, Mombasa, Kenya]). 
If anaemia was diagnosed, it was treated with increased 
supplementation with either two to three combination 
tablets of iron-folic acid per day or with Hemovit multivi-
tamin syrup (200 mg ferrous sulfate, 0.5 mg B6, 50 µg B12, 
1.5 mg folic acid and 2.33 mg zinc sulfate per 5 mL [Shelys 
Pharmaceuticals, Dar es Salaam, Tanzania]) in a dose of 
10 mL two to three times daily depending on severity.
blood sample collection
Venous blood was collected in EDTA and serum tubes at 
the time of inclusion, all antenatal visits, delivery, neonatal 
visits if cord blood was missed and paternal visits (EDTA 
tube only). Serum tubes were kept light-protected and all 
blood samples were kept at 2°C–8°C until processed at 
KDH within 2 hours of collection.
Hb was measured at the time of inclusion, all antenatal 
visits and delivery. Bilirubin, ferritin, folic acid, vitamin 
B12, alanine aminotransferase, C reactive protein and 
albumin were measured at the time of inclusion, 32–34 
weeks of gestation and delivery. Sampling of placental 
development markers (VEGF-A, Soluble fms-like tyro-
sine kinase-1 [sFlt-1], PlGF, Pregnancy‐associated plasma 
protein A [PAPP-A]) was performed at inclusion into the 
pregnancy study if before GA 11 weeks, at 11–14 weeks, 
20–22 weeks and 26–28 weeks of gestation and delivery. 
Blood sampling for fetal growth markers (IGF-1, IGF-2, 
Insulin Like Growth Factor Binding Protein 1 [IGFBP1]) 
was performed at inclusion into the pregnancy study, 
11–14 weeks, 26–28 weeks and 32–34 weeks of gestation 
and delivery in both venous and cord blood.
ultrasound
Serial, transabdominal ultrasound was used to esti-
mate GA using crown-rump length in the first trimester 
and head circumference in the second trimester.31 32 If 
included before week 11 of pregnancy, the GA was esti-
mated again between weeks 11–14. Ultrasound for fetal 
weight was performed at GA of 20–22 weeks, 26–28 
weeks, 32–34 weeks and 37–39 weeks of pregnancy. Addi-
tional ultrasound was done if intrauterine growth retar-
dation was suspected and biweekly until delivery for all 
women diagnosed with gestational diabetes. The Hadlock 
formula on head circumference, abdominal circumfer-
ence and femur length was used for weight estimation.33 
Placental blood flow was estimated using both uterine 
and umbilical artery blood flow with pulsatile and resis-
tance index as well as the systolic-diastolic ratio each time 
fetal weight was estimated. Uterine blood flow was also 
evaluated at weeks 11–14 and diastolic notching noted at 
each investigation.34 35
newborn examination
At the time of delivery and at 4–6 weeks postnatally, 
weight, length, head circumference, abdominal circum-
ference, mid upper arm circumference, skinfold thickness 
of biceps, triceps, subscapular and thigh of the newborn 
were measured. Newborn assessment was performed 
within 24 hours, and, if delayed due to home delivery, as 
soon as possible. Z-scores were estimated using a refer-
ence chart produced for Tanzania in the STOPPAM Study 
and the Intergrowth-21st reference charts.30 36–38
Cord blood and placenta samples for genetic analyses
Cord blood samples were collected in EDTA, serum 
and PAXgene tubes, primarily before the placenta was 
born. The placenta was processed within 15–20 min after 
delivery at the hospital, and for home deliveries within 
2 hours, when possible. EDTA tubes were placed cold 
directly after collection and processed within 2 hours, 
including collection of buffy coat. PAXgene tubes were 
stored at room temperature for 2 hours, and subsequently 
at −20°C for 24–72 hours, before storage at −80°C.
The cord and amnion were removed, and the placenta 
was weighed. Using a biopsy punch, biopsies were 
collected from each quadrant, from the cord inser-
tion and at the edge of the placenta at the area furthest 
from cord insertion. Each biopsy was washed with saline 
solution and divided into the maternal and fetal side. A 
~1 cm3 cord tissue sample was collected from the cord 
end closest to insertion. All biopsies were snap frozen in 
liquid nitrogen and stored at −80°C. The placentas were 
macroscopically examined for signs of disrupted develop-
ment. Membranes, cord, placental size, thickness, shape 
and parenchyma infarcts were described. Pictures of each 
placenta were taken to document morphology.
Genome-wide DNA methylation and RNA expression 
will be performed in cord blood and placenta biopsies 
using Illumina Infinium MethylationEPIC arrays and 
RNA sequencing on Illumina Nextseq. Genome-wide 
association studies will also be performed in both cord 
blood and maternal blood using CoreExome/OmniEx-
pressExome Illumina arrays.
stereological placenta samples
Ten full-depth placental tissue blocks were collected 
using systematic uniform random sampling and vertical 
sectioning, and conserved in 10% formalin. Isotropic 
uniform random sampling and Mattfeldt orientator was 
used to collect slides for paraffin embedding.39 Infor-
mation of the sample position was collected regarding 
whether the sample block was from the placental 
periphery or centre. The slides were orientated so the 
vertical section contained both the maternal and fetal 
sides. The tissue was immunohistochemically stained with 
CD34 to visualise the vessels. Stereological analysis will 
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be applied to assess the placental vascular morphology 
in placentae from women with or without anaemia and/
or malaria during pregnancy. The total villi volume and 
vessel length, surface and diameter of transport and diffu-
sion villi, will be examined.
legal and ethical aspects
Explanation about the study was given to village leaders 
and community members before women were invited. 
After giving oral information, written informed consent 
(or thumbprints of illiterate women) was obtained prior 
to enrolment. All procedures were conducted in accor-
dance with the Declaration of Helsinki. All participants 
were treated according to Tanzanian national guidelines. 
Antenatal and perinatal care followed guidelines from 
The National Road Map Strategic Plan.40 The project 
assisted all participants in obtaining the best local medical 
care available if disease was diagnosed.
Patients and public society were not involved in the 
design of this study.
statistics
Assumptions of equal variance and normally distributed 
residuals will be visualised in Q-Q plots and histograms. 
For univariate analyses, normally distributed data will be 
presented as mean±SD and compared by Student's t-test, 
whereas non-normally distributed data will be presented 
as median and IQR and compared by the Mann-Whitney 
U test. Proportions of categorical data will be compared 
using χ2 test. For multivariate analyses on risk factors 
for poor preconceptional health, and analyses on the 
effect of anaemia and malaria on fetal and stereological 
outcomes, multivariate regression analysis will be used. 
If appropriate, mixed regression modelling will be used 
on repeated outcome measures including fetal growth 
trajectories and biomarkers of placental and fetal devel-
opment. For epigenetic analyses, appropriate bioinfor-
matic analyses will be used taking into consideration the 
false discovery rates.
FIndIngs to dAte
Preconception study characteristics
Of the 2629 women screened, 1415 were included in the 
preconception study (figure 3). Main causes for exclu-
sion were use of modern contraception methods (27%) 
and age eligibility (26%). Among the 1415 women, 72 
did not have venous blood collected at preconception, 
34 had an ultrasound dated GA that showed they were 
already pregnant at time of inclusion (although very early 
in pregnancy) and 50 never had GA estimated with ultra-
sound. Additionally, 11 women were later found not to 
meet all inclusion criteria, leaving 1248 truly preconcep-
tion women to be included in the final analyses (figure 3 
and table 2). Average age, body mass index and BP of 
the 1248 preconception women were 28 years, 23 kg/
m2 and 117/75 mm Hg, respectively (table 2). In total, 
458 (36.7%) women had anaemia (Hb <12 g/dL) and 34 
(3.6%) women were diagnosed as HIV-positive (table 2). 
Soil transmitted helminths were detected in 13 (2.7%) 
women.
Pregnancy study characteristics
A total of 2995 third monthly visits were conducted for 
the 1415 women. During these follow-up visits, additional 
134 women were excluded for various reasons (figure 3). 
In total 417 women were later found pregnant and 383 
women were followed during pregnancy (figure 3). 
Further, 155 women were included in the pregnancy study 
within the first 14 weeks of pregnancy, in a ratio of 1:1 
(mild, moderate or severe anaemia versus non-anaemic). 
Of the 155 women, 7 had severe anaemia (Hb ≤8 g/dL), 
71 had mild–moderate anaemia (Hb 8.1–10.9 g/dL) and 
77 were non-anaemic (Hb ≥11 g/dL). In total, 538 women 
were included in the pregnancy study (figure 3).
During pregnancy, 359 (66.7%) women had anaemia 
(Hb <11 g/dL) of which 85 (15.8%) women had moder-
ate-to-severe anaemia (Hb ≤9 g/dL) and 33 (6.3%) had 
severe anaemia (Hb ≤8 g/dL). In total, 185 (34.4%) 
women were diagnosed with malaria and 17 (3.4%) 
women were diagnosed with HIV during pregnancy. In 
total, 147 (27.3%) women were non-anaemic and never 
had malaria throughout pregnancy (table 3).
birth study characteristics
Of the 538 pregnancies (figure 3), 80 women had a miscar-
riage (16%), of which 72 were early (≤14 weeks) and 8 
were late (>14 weeks, ≤22 weeks)—5 without and 3 with 
pregnancy outcome data collected at the time of miscar-
riage (figure 3 and table 3). The birth cohort consisted 
of 427 women (79%) having given birth to 438 neonates 
including the 3 women who had a late miscarriage at the 
hospital and complete outcome data collected.
For the 424 women who had given birth after week 22 
of gestation, the average GA was 280 days, and 27/424 
(6.4%) women delivered preterm (>22 weeks, <37 weeks). 
Average birth weight was 3016 g and 10.3% were born 
with LBW (<2500 g) among singleton live births without 
congenital anomalies. Twelve deliveries were stillbirths. 
Neonatal data were collected on 421 of the 426 live births 
(99%) (table 3 and figure 3). Among the 421 neonates 
with follow-up data, 13 neonates did not survive until 
day 28. For the remaining 408, neonatal anthropometric 
measurements were documented for 400 (98%) (table 3 
and figure 3).
Only women with data on time of delivery/late miscar-
riage were considered potential for paternal follow-up, 
which was performed for 113 fathers (table 3 and 
figure 3).
strengths And lImItAtIons
The uniqueness of this study lies in the establishment of 
a population that is followed continuously before and 
during pregnancy with an accurate estimation of GA 
using early ultrasound, and includes detailed, high-quality 
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Figure 3 Overview of study cohort. Number of women screened, included and excluded in the preconception and pregnancy 
study. ¤: venous blood samples were not collected for 72 women at time of inclusion and were therefore excluded in the final 
analyses of the preconception study. #: 50 women were excluded because they never had GA estimation with US performed 
(this included 4 of the 6 women who refused inclusion into the pregnancy study, the 16 women who had an ongoing miscarriage 
when found pregnant, 18 women who had a miscarriage after inclusion into the pregnancy study and the 12 women who had a 
miscarriage in between preconception follow-up visits). *34 women were excluded because the US dated GA showed that they 
were already pregnant at the time of inclusion. GA, gestational age; Hb, haemoglobin; US, ultrasound.
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data of fetal weight and placental blood flow monitoring, 
stringent screening for development of hypertension or 
diabetes, and a substantial biobank of plasma, serum, cord 
blood and placenta, including stereology and epigenetic 
markers, which to our knowledge have not been collec-
tively studied before in a rural African setting. Anaemia 
before, during and after pregnancy is much more prev-
alent in LMICs, compared with high-income countries 
(HICs) which mainly have high prevalence of anaemia 
during pregnancy.4
Table 2 Maternal characteristics in preconception study
Maternal characteristics 
at inclusion
Women in 
preconception 
cohort with blood 
collected before 
conception, n=1248
n included in 
calculations
Age (years) 28 (22–34) 1233
Height (cm) 155 (152–159) 1240
Weight (kg) 55.2 (48.8–63.7) 1239
Maternal preconception/first 
antenatal visit BMI (kg/m2)
22.7 (20.4–26.3) 1231
Systolic blood pressure 
(mm Hg)
116.8 (11.0) 1233
Diastolic blood pressure 
(mm Hg)
75.1 (8.8) 1233
Parity 2 (1–4) 1242
Ethnicity 1247
Sambaa 424
Zigua 405
Others* 418
Education 1247
  None or incomplete 
primary
241 (19.3)
  Complete primary 787 (63.1)
Secondary or higher 219 (17.6)
Source of domestic water 1244
  Private tap or bore hole 106 (8.5)
  Public tap or bore hole 809 (65.0)
  River/pool 329 (26.5)
Type of toilet facility 1246
  Flush 312 (25)
  Pit 923 (74.1)
  None 11 (0.9)
Haemoglobin (mmol/l) 12.2 (1.5) 1233
Anaemia (<12 g/dL) 458 (36.7%) 1248
Malaria at enrolment 101 (8.1%) 1244
Non-anaemic and malaria-
negative at enrolment
734 (59.0%) 1244
Diabetes mellitus 10 (0.8%) 1232
HIV-seropositive 54 (5.7%) 952
Data are presented as mean (±SD), median (IQR) or n (%).
*All other tribe groups include tribes with <10% prevalence.
BMI, body mass index.
Table 3 Maternal and birth characteristics and available 
samples, in the pregnancy study
Maternal characteristics 
at inclusion
Pregnancy cohort, 
n=538
n included in 
calculations
Age (years) 27 (23–33.5) 532
Height (cm) 156 (152–159) 535
Weight (kg) 55.6 (49.1–63.8) 531
Maternal first antenatal 
visit BMI (kg/m2)
23 (20.5–26.1) 528
Systolic blood pressure 
(mm Hg)
112 (12) 535
Diastolic blood pressure 
(mm Hg)
71 (10) 535
Parity 2 (1–4) 538
Ethnicity 538
Sambaa 198
Zigua 173
Others* 128
Education 538
  None or incomplete 
primary
122 (22.7)
  Complete primary 359 (66.7)
  Secondary or higher 57 (10.6)
Source of domestic water 536
  Private tap or bore hole 25 (4.7)
  Public tap or bore hole 369 (68.8)
  River/pool 142 (26.4)
Type of toilet facility 536
  Flush 160 (29.9)
  Pit 370 (69.0)
  None 6 (1.1)
Diabetes mellitus (known) 2 (0.4) 538
HIV-seropositive 17 (3.4%) 500
Pregnancy and birth 
characteristics
Gestational age (days) at 
enrolment
63 (45–85) 517†
Anaemia during 
pregnancy (Hb<11 g/dL)
359 (66.7%) 538
Moderate-severe anaemia 
during pregnancy (Hb≤9 g/
dL)
85 (15.8%) 538
Severe anaemia during 
pregnancy (Hb≤8 g/dL)
33 (6.3%) 538
Malaria during pregnancy 185 (34.4%) 538
Early miscarriage 
(GA≤14 weeks)
72 (13.4%) 538
Late miscarriage (GA>14 
weeks, GA≤22 weeks)
8‡ (1.5%) 538
Delivery 427
  At hospital 369 (86.4%)
  At home 45 (10.5%)
  At dispensary 13 (3.0%)
Continued
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There are only few previous preconception birth cohort 
studies in sub-Saharan African countries, with participant 
numbers ranging from n=30 to n=376.26 41–43 These do 
not include data as comprehensive as in our study and 
do not include continuous ultrasound examinations, 
and biological sampling for both placenta stereology and 
epigenetics. To the best of our knowledge our present 
cohort study is the largest in sample size conducted in a 
sub-Saharan African country, with preconceptional data. 
The uniqueness of this cohort in contrast to other large 
birth cohort studies from more developed countries is 
the high co-occurrence of malaria and anaemia as well 
as presence of HIV, allowing us to study these exposures 
separately as well as simultaneously. Notably, few studies 
have been undertaken, exploring the potentially modifi-
able risk factor of anaemia for NCDs in later life through 
epigenetic monitoring.
The aims of this study include use of fetal and placental 
growth markers and epigenetic changes as end points in 
analyses of the effect of anaemia of fetal health. However, 
we acknowledge that these measurements are only proxy 
markers for future NCDs. It will be highly important to 
follow up the children of this cohort to further investi-
gate the outcome of developmental programming with 
focus on risk markers of NCDs, for example, hyperten-
sion, metabolic profile and obesity. Longitudinal studies, 
commencing prior to conception and with continuous 
follow-up, are indeed required to unravel the potentially 
complex interplay between maternal health and offspring 
epigenetic profile to understand how epigenetic mecha-
nisms may contribute to disease risk.
We succeeded in recruiting more pregnant women 
than expected, but with a lower prevalence of anaemia 
than anticipated, therefore some outcomes may have 
less power including birth outcomes in severe anaemia. 
Yet, the higher number of mild anaemia cases might 
relate more to areas of the world where mild pregnancy 
anaemia prevails, so our subsequent analyses may reveal 
if even slight decrease of Hb may have adverse effects. In 
addition, with this study design, we will be able to account 
for the effects of moderate-to-severe anaemia versus mild 
anaemia, versus no anaemia as well as high Hb concen-
trations. Still it is important to recognise that causes of 
anaemia may highly vary from LMICs to more western-
ised countries, that is, Denmark, and therefore the conse-
quences of anaemia may also be different.
Although several studies report that prenatal anaemia 
is associated with adverse birth outcomes,5 10 prenatal iron 
deficiency is not necessarily associated with neonatal iron 
deficiency, as shown in a recent randomised control study 
by Angulo-Barosso et al.44 To account for the dynamics 
of iron deficiency during pregnancy, we have obtained 
repeated measurements of iron and Hb concentrations 
at preconception and throughout pregnancy. Cord blood 
serum and plasma are also stored and available for future 
measurements of iron markers. Therefore, we will be 
able to include the iron and Hb dynamics in subsequent 
analyses, which will improve the understanding of how 
maternal iron deficiency may or may not lead to fetal iron 
deficiency and adverse birth outcomes.
In conclusion, the FOETALforNCD Study includes 
interdisciplinary and transgenerational approaches 
enabling us to understand effects of anaemia and/
or malaria on fetal development and programming for 
Maternal characteristics 
at inclusion
Pregnancy cohort, 
n=538
n included in 
calculations
Caesarean section 35 (8.2%) 426
Newborns delivered 438 (410 singleton, 28 
twins)
427 women
Sex (boys) 206 (48.5%) 425
Gestational age (days) at 
delivery (GA>22 weeks)
280 (274–286) 424§
Preterm delivery 
(GA>22 and GA<37 weeks)
27 (6.4%) 424§
Birth weight (g)¶ 3016 (486) 379
Low birth weight≤2500 g¶ 39 (10.3%) 379
Stillbirth# 12 435
Neonatal death (before 
28 days)¶
13 423
Perinatal mortality rate 
(stillbirth+first 7 days of 
life)¶
53/1000 435
Neonatal anthropometry 
after 28 days of life
400 410
Paternal follow-up 113
Blood samples, biopsies and stereology
Inclusion 534 538
GA 11–14 weeks 259 276
AV 2 (GA 20 weeks) 389 391
AV 3 (GA 26 weeks) 391 393
AV 4 (GA 32 weeks) 404 404
AV 5 (GA 37 weeks) 367 370
Delivery 410 427
Cord blood** 366 438
Placental epigenetic 
samples**
395 427
Placental stereology 
samples‡
393 427
Data are presented as mean (SD), median (IQR) or n (%). 
*Includes: all other tribe groups including tribes with 
<10% prevalence.
†Among the 538 women 21 had a positive UPT on inclusion 
into the pregnancy study but had a miscarriage before GA was 
estimated by ultrasound evaluation.
‡Three of these participants had a very late miscarriage with 
complete delivery data collected, and are therefore included in the 
total number of 427 deliveries.
§Three late miscarriages are excluded.
¶Includes: singleton, live births, no major malformation, GA >22 
weeks.
**Includes: all neonates (singleton + twins).
AV, antenatal visit; BMI, body mass index; GA, gestational age; Hb, 
haemoglobin. 
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NCDs, including epigenetic mechanisms. The study is 
expected to shed light on the mechanisms behind the 
rapid epidemiological transitions in LMICs and whether 
risk factors for NCDs, beyond those well known from 
HICs, may have to be included to control NCDs in the 
next generations.
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